Australia's Mayne Pharma gains on flagging no material impact from latest US tariffs

Mayne Pharma

07/04/2026 02:04

** Mayne Pharma MYX.AX gains as much as 4.7% to A$2.45, highest since April 2

** Stock marks biggest intraday pct gain since April 1

** Co expects no material impact to FY27 earnings profile from New Section 232 tariff proclamation announced by Donald Trump

** Trump signed executive order imposing 100% tariffs on branded pharma products imported into U.S. unless makers agree to government drug pricing deals or commit to making their products domestically

** YTD, MYX down 21.5%

 (Reporting by Nichiket Sunil in Bengaluru)

 ((Nichiket.Sunil@thomsonreuters.com))